Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Shares and Warrants (Tables)

Common Shares and Warrants (Tables)

9 Months Ended

May 31, 2021

Common Shares and Warrants

Schedule of fair value of purchase warrants

		May 31 2021

Expected volatility			103	%
Risk-free interest rate			0.16	%
Expected life		3 years
Dividend yield			0	%
Estimated fair value per warrant		$	2.62

Sehedule of warrants

Type of Issuance

Number of

Shares

Exercise

Price

Total Value

Warrants

300,000

$9.00

$

785,895

300,000

$

785,895

Schedule of warrants issued

		Number of Warrants				Weighted Average Exercise Price $
Balance August 31, 2019			94,177				41.40
Cancelled/expired			(25,000	)			44.90
Issued			402,431				12.74
Balance August 31, 2020			471,608				16.77
Cancelled/expired			(44,161	)			67.50
Issued			2,630,017				6.58
Balance May 31, 2021			3,057,464				7.87

Schedule of warrants outstanding

# of Warrants				Weighted Average Remaining Contractual Life		Weighted Average Exercise Price $
	25,000			0.36 years			4.20
	292			0.45 years			36.00
	7,500			1.43 years			24.00
	300,000			2.88 years			9.00
	51,814			3.46 years			36.00
	8,984			3.50 years			36.00
	16,667			3.79 years			9.00
	317,190			3.93 years			10.50
	2,330,017			4.63 years			6.58
	3,057,464			4.32 years			7.85